Immunohistochemical expression of embryonic stem cell markers in malignant rhabdoid tumors

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Malignant rhabdoid tumor is a highly aggressive pediatric neoplasm molecularly characterized by inactivating mutations of the SMARCB1 gene, a potent tumor suppressor and member of the SWI/SNF chromatin remodeling complex. It has been suggested that oncogenesis in SMARCB1-deficient cancers, such as malignant rhabdoid tumors, is driven not by the loss of SWI/SNF function but by an aberrant functioning of the BRG1-containing SWI/SNF complex. Since Brg1 is required for self-renewal and pluripotency of mouse embryonic stem cells, we hypothesized that the human malignant rhabdoid tumors may express pluripotency genes such as SALL4, LIN28, OCT3 and OCT4 (OCT3/4), NANOG, and TCL1. To test this hypothesis, we studied the immunohistochemical expression of SALL4, LIN28, OCT3/4, NANOG, and TCL1 in 11 malignant rhabdoid tumors of the central nervous system (atypical teratoid/rhabdoid tumors) and 5 malignant rhabdoid tumors of the kidney. Of the 16 malignant rhabdoid tumors, 14 (88%) tumors showed robust SALL4 and/or LIN28 expression. No tumor showed any significant OCT3/4, NANOG, or TCL1 expression. Our results suggest that malignant rhabdoid tumors may arise from and/or share features with embryonic stem cells or germ cells.

Original languageEnglish (US)
Pages (from-to)353-359
Number of pages7
JournalPediatric and Developmental Pathology
Volume14
Issue number5
DOIs
StatePublished - Dec 1 2011

    Fingerprint

Keywords

  • Atypical teratoid/rhabdoid tumor
  • Central nervous system
  • Kidney
  • LIN28
  • Malignant rhabdoid tumor
  • SALL4

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine

Cite this